Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to $457.7 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Financing Activities fell 95.57% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year decrease of 90.93%. This contributed to the annual value of $457.7 million for FY2024, which is 102.83% up from last year.
  • Viridian Therapeutics, Inc.\DE's Cash from Financing Activities amounted to $457.7 million in FY2024, which was up 102.83% from $225.7 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities ranged from a high of $457.7 million in FY2024 and a low of $101.3 million during FY2020.
  • Its 3-year average for Cash from Financing Activities is $335.2 million, with a median of $322.2 million in 2022.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 144,630.00% in 2020, then declined by 29.97% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities (Yearly) stood at $101.3 million in 2020, then climbed by 23.65% to $125.3 million in 2021, then skyrocketed by 157.23% to $322.2 million in 2022, then dropped by 29.97% to $225.7 million in 2023, then soared by 102.83% to $457.7 million in 2024.